BRPI0610912A2 - anticorpos anti-il2 - Google Patents

anticorpos anti-il2

Info

Publication number
BRPI0610912A2
BRPI0610912A2 BRPI0610912-8A BRPI0610912A BRPI0610912A2 BR PI0610912 A2 BRPI0610912 A2 BR PI0610912A2 BR PI0610912 A BRPI0610912 A BR PI0610912A BR PI0610912 A2 BRPI0610912 A2 BR PI0610912A2
Authority
BR
Brazil
Prior art keywords
human
monoclonal antibody
humanized monoclonal
binding
amino acid
Prior art date
Application number
BRPI0610912-8A
Other languages
English (en)
Inventor
Patrick Baeuerle
John Lumsden
Stefan Pflanz
Tobias Raum
Joerg Volkland
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of BRPI0610912A2 publication Critical patent/BRPI0610912A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)

Abstract

ANTICORPOS ANTI-IL2. A invenção diz respeito a um anticorpo monoclonal humanizado, ou seus fragmentos, que se liga especificamente a interleucina-2 (IL2) humana, em que o dito anticorpo mono- clonal humanizado neutraliza a atividade da IL2 humana se ligando à dita IL2 humana antes, durante ou subseqti.ente à ligação da dita IL2 humana ao receptor IL2 humano, e em que a região variável de cadeia leve do dito anticorpo monoclonal humanizado compreende em sua segunda região de estrutura a seqUência contígua de aminoácido KAPKA nas posições de aminoácido 42-46.
BRPI0610912-8A 2005-06-01 2006-05-31 anticorpos anti-il2 BRPI0610912A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05011845 2005-06-01
PCT/EP2006/005194 WO2006128690A1 (en) 2005-06-01 2006-05-31 Anti-il2 antibodies

Publications (1)

Publication Number Publication Date
BRPI0610912A2 true BRPI0610912A2 (pt) 2008-12-02

Family

ID=37025008

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610912-8A BRPI0610912A2 (pt) 2005-06-01 2006-05-31 anticorpos anti-il2

Country Status (15)

Country Link
US (1) US7964707B2 (pt)
EP (1) EP1888644A1 (pt)
JP (1) JP5414271B2 (pt)
KR (1) KR101340559B1 (pt)
CN (1) CN101189265B (pt)
AU (1) AU2006254333B2 (pt)
BR (1) BRPI0610912A2 (pt)
CA (1) CA2609234C (pt)
IL (1) IL187316A0 (pt)
MX (1) MX2007014565A (pt)
NO (1) NO20076568L (pt)
NZ (1) NZ563213A (pt)
RU (1) RU2425054C2 (pt)
WO (1) WO2006128690A1 (pt)
ZA (1) ZA200709456B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33194B1 (fr) * 2009-03-16 2012-04-02 Cephalon Australia Pty Ltd Anticorps humanisés ayant une activité antitumorale
EP2496257A4 (en) * 2009-11-05 2013-02-27 Cephalon Australia Pty Ltd TREATMENT OF CANCER CHARACTERIZED BY THE MUTATION OF KRAS OR BRAF GENES
US9243060B2 (en) 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized anti-factor C3b antibodies and uses thereof
US10011652B2 (en) 2013-12-12 2018-07-03 Umc Utrecht Holding B.V. Immunoglobulin-like molecules directed against fibronectin-EDA
MX2016008472A (es) 2013-12-26 2016-10-28 Mitsubishi Tanabe Pharma Corp Anticuero monoclonal neutralizador de anti-il-33-humana.
CA2954476C (en) 2014-07-10 2023-09-19 Novartis Ag Immune-stimulating monoclonal antibodies against human interleukin-2
CN109071648B (zh) * 2015-10-23 2022-07-19 辉瑞有限公司 抗il-2抗体及其组合物和用途
CN108473569B (zh) 2016-01-11 2022-11-22 苏黎世大学 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
AR108975A1 (es) 2016-07-06 2018-10-17 Celgene Corp Anticuerpos con baja inmunogenicidad y sus usos
JP2019534710A (ja) 2016-09-28 2019-12-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インターロイキン２に結合する抗体およびその使用
CN110914297B (zh) * 2017-05-25 2023-06-06 基础科学研究院 抗人白细胞介素2抗体及其用途
JP7177446B2 (ja) 2017-08-31 2022-11-24 田辺三菱製薬株式会社 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤
CA3135992C (en) * 2019-06-10 2024-02-13 Shandong Boan Biotechnology Co., Ltd. Anti-cd25 antibody and application thereof
CN117157312A (zh) 2021-03-30 2023-12-01 豪夫迈·罗氏有限公司 蛋白酶活化的多肽
CN116284380A (zh) * 2021-05-14 2023-06-23 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
WO2024068705A1 (en) 2022-09-29 2024-04-04 F. Hoffmann-La Roche Ag Protease-activated polypeptides
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090193A1 (en) * 2000-05-24 2001-11-29 Smithkline Beecham Corporation Sialoadhesin factor-3 antibodies
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
EP1578397B1 (en) * 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
AU2004264953B2 (en) * 2003-08-13 2009-07-23 Novartis Vaccines And Diagnostics, Inc. Prion-specific peptide reagents

Also Published As

Publication number Publication date
RU2425054C2 (ru) 2011-07-27
WO2006128690A1 (en) 2006-12-07
IL187316A0 (en) 2008-04-13
NO20076568L (no) 2008-02-19
CA2609234C (en) 2014-04-22
JP2008542321A (ja) 2008-11-27
NZ563213A (en) 2009-07-31
ZA200709456B (en) 2008-08-27
CN101189265A (zh) 2008-05-28
CN101189265B (zh) 2012-07-04
JP5414271B2 (ja) 2014-02-12
CA2609234A1 (en) 2006-12-07
AU2006254333B2 (en) 2011-02-17
KR101340559B1 (ko) 2013-12-11
MX2007014565A (es) 2008-02-11
AU2006254333A1 (en) 2006-12-07
US7964707B2 (en) 2011-06-21
KR20080032046A (ko) 2008-04-14
US20080317746A1 (en) 2008-12-25
EP1888644A1 (en) 2008-02-20
RU2007143996A (ru) 2009-07-20

Similar Documents

Publication Publication Date Title
BRPI0610912A2 (pt) anticorpos anti-il2
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
UY33089A (es) PROTEÍNAS DE ENLACE A ANTÍGENOS HUMANAS QUE ENLAZAN B(beta)-KLOTHO, RECEPTORES FGF Y COMPLEJOS DE LOS MISMOS
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
BRPI0611414B8 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
BR122018012430B8 (pt) anticorpo monoclonal que se liga a pcsk9 humana, e, composição farmacêutica
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
CR8958A (es) Anticuerpos Anti-5T4 humanizados y conjugados de anticuerpos anti-5T4/caliqueamicina
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
RS51468B (en) COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137)
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
CR20130152A (es) Proteínas de la unión a il-12/p40 (divisional 9599)
BRPI0710645A2 (pt) Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
AR078650A1 (es) Anticuerpo de union a il-1 beta
RS52860B (en) ANTI-ILT7 ANTITELO
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: MICROMET AG (DE)

Free format text: A FIM DE ATENDER AS ALTERACOES DE NOME REQUERIDAS ATRAVES DA PETICAO NO 20120113062/RJ, DE 06/12/2012, E NECESSARIO APRESENTAR MAIS UMA GUIA RELATIVA A SEGUNDA ALTERACAO DE NOME, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: MICROMET GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: AMGEN RESEARCH (MUNICH) GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]